VeracyteのCEOとCFOは、好調な決算と好調な株価パフォーマンスの中で株式を売却しました。 CEO and CFO of Veracyte sold shares amid strong earnings and positive stock performance.

2025年12月4日,VeracyteのCEOであるMarc Stapleyは7,668株を47.09ドルで売却し,その株価を2.35%削減し,CFOであるRebecca Chambersは13,278株を46.84ドルで売却し,その保有額を10.81%削減した. On December 4, 2025, Veracyte CEO Marc Stapley sold 7,668 shares at $47.09 each, reducing his stake by 2.35%, while CFO Rebecca Chambers sold 13,278 shares at $46.84, cutting her holding by 10.81%. 両方の取引は 証券取引委員会に提出された Both transactions were filed with the SEC. 同社は11月4日から第3四回の強大な収入を報告し,50.51 EPS及び131.87万円の収入,年度13. 8%上昇. The company reported strong third-quarter earnings on November 4, with $0.51 EPS and $131.87 million in revenue, up 13.8% year-over-year. Veracyteの株価は12月4日に47.41ドルで閉店し,0.34ドル下落し,市場資本額は37億5千万ドルで,コンセンサス"中等買い"の評価を得ました. Veracyte’s stock closed at $47.41 on December 4, down $0.34, with a market cap of $3.75 billion and a consensus “Moderate Buy” rating.